Company / R&D Expense
Entrada Therapeutics, Inc. R&D Expense History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$125.3M
FY2025
5-year range
$66.6M / $125.3M
FY2023-FY2025
Trend
+25.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $67M to $125M over the past 2 years.
Based on SEC 10-K filings.
$125M in FY2025.
Improved from $67M to $125M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d expense increased 25.5% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $125.3M | +25.5% |
| FY2024 | $99.9M | +50.0% |
| FY2023 | $66.6M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026